ANGLE PLC’s (LON:AGL OTCQX:ANPCY) cancer cell collection technology has received another encouraging peer review in a leading scientific journal.
The University Medical Centre Hamburg-Eppendorf (UKE) published new research detailing the use of ANGLE's Parsortix system in the Clinical Chemistry journal.
ANGLE's chief executive, Andrew Newland, said: "This fourth peer-reviewed publication in a key scientific journal adds to the growing body of published evidence of
Parsortix's superior performance as a liquid biopsy.
"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine.
“By facilitating the determination of which drugs will benefit individual patients and which will have little clinical benefit yet cause significant side effects, such protocols will also help reduce the burden on expensive healthcare resources."
Klaus Pantel, chairman, Department of Tumour Biology at UKE's Centre of Experimental Medicine, added: "We are excited about the new workflows utilising Parsortix to study multi marker profiles of single CTCs by low cost qPCR approaches.
“The high expression levels of chemokines achieved with Parsortix offers the potential for its use in therapy selection for patients and we will be progressing further studies to determine specific applications."